Metamizol Teva (Metamizole Sodium Monohydrate)

The exact mechanism of metamizole is not fully understood. It is believed to inhibit cyclooxygenase enzymes, reducing prostaglandin production, and to influence endogenous opioid pathways, which together contribute to its pain‑relieving and fever‑reducing effects.

The appropriate dose of Metamizol Teva is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and clinical response. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for metamizole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after evaluating individual circumstances.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metamizol offers strong analgesic and antipyretic effects similar to other non‑opioid pain relievers but differs by having a lower risk of gastrointestinal irritation. However, it carries a unique risk of agranulocytosis, which is less common with many NSAIDs, so safety monitoring is essential.

Metamizol Teva should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Metamizol Teva is administered orally. The tablet or liquid is taken with water, following the dosage prescribed by the healthcare professional. It should be swallowed whole unless the product label specifies otherwise.

The most serious adverse effect is agranulocytosis, a potentially life‑threatening drop in white blood cells. Other severe risks include Stevens‑Johnson syndrome, anaphylactic reactions, and significant liver or kidney impairment. Prompt medical attention is required if symptoms of these conditions appear.

Metamizol Teva should be avoided in individuals with known hypersensitivity to metamizole or any of its components, in patients with a history of agranulocytosis, and in those taking other myelotoxic drugs without close monitoring. Pregnant or breastfeeding women should use it only under strict medical supervision.